Wide Ranks

ACRV

Acrivon Therapeutics, Inc.

7.52

Top Statistics
Market Cap 234 M Forward PE -2.54 Revenue Growth 0.00 %
Current Ratio 16.16 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.11 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 180 M Total Cash Per Share 5.83 Total Debt 4 M
Total Debt To Equity 1.95 Current Ratio 16.16 Book Value Per Share 5.38
All Measures
Short Ratio 1538.00 % Message Board Id finmb_652690313 Shares Short Prior Month 1 M
Return On Equity -0.3778 City Watertown Uuid ec97dcba-7584-3161-bbe1-36f5f444af3c
Previous Close 7.35 First Trade Date Epoch Utc 1 B Book Value 5.38
Total Debt 4 M Volume 49975 Price To Book 1.40
Fifty Two Week Low 3.19 Total Cash Per Share 5.83 Shares Short Previous Month Date 1 B
Target Median Price 22.00 Audit Risk 6 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Target Mean Price 21.56
Net Income To Common -69002000 Short Percent Of Float 0.0915 Implied Shares Outstanding 31 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 51810
Average Volume10days 51810 Total Cash 180 M Next Fiscal Year End 1 B
Held Percent Insiders 0.2239 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 7.35
Target Low Price 16.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.51
Open 7.54 Free Cashflow -31308376 State MA
Dividend Yield 0.00 % Return On Assets -0.2441 Time Zone Short Name EST
Board Risk 8 Trailing Eps -2.66 Day Low 7.21
Address1 480 Arsenal Way Shares Outstanding 31 M Compensation Risk 9
Price Hint 2 Target High Price 30.00 Website https://www.acrivon.com
52 Week Change 0.8568 Average Volume 88192 Forward Eps -2.70
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1599.90 %
Is_sp_500 False Regular Market Day High 7.70 Profit Margins 0.00 %
Debt To Equity 1.95 Fifty Two Week High 11.90 Day High 7.70
Shares Short 1 M Regular Market Open 7.54 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0348
Operating Cashflow -53158000 Currency USD Time Zone Full Name America/New_York
Market Cap 234 M Is_nasdaq_100 False Zip 02472
Quote Type EQUITY Industry Biotechnology Long Name Acrivon Therapeutics, Inc.
Overall Risk 9 Regular Market Day Low 7.21 Held Percent Institutions 0.7598
Current Price 7.52 Address2 Suite 100 Enterprise To Ebitda -1.11
Financial Currency USD Current Ratio 16.16 Industry Disp Biotechnology
Number Of Analyst Opinions 9 Country United States Float Shares 11 M
Two Hundred Day Average 7.44 Governance Epoch Date 1 B Enterprise Value 83 M
Forward PE -2.54 Regular Market Volume 49975 Ebitda -75561000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.

The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.

The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor.

Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.